HIV and AIDS MAIN SECTION 1
    
 Google Custom Search
Lower Global HIV Numbers Reflect More Accurate Estimation Methods 


By Liz Highleyman

As they do every year to coincide with World AIDS Day on December 1, the Joint United Nations Program on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) released updated statistics this week on the number of people estimated to be living with HIV worldwide.

A surprise in this year’s figures was the dramatic drop in the estimated total number of people with HIV, from 39.5 million in 2006 to 33.2 million in 2007 -- a decrease of more than 6 million. The agencies also estimated that about 2.5 million people will be newly infected with HIV this year (about 40% fewer than previously estimated), and some 2.1 million will die of HIV/AIDS-related causes.

According to UNAIDS and WHO, the number of new HIV infections likely peaked in the late 1990s, and then slowly declined due to factors such as effective prevention programs and the virus reaching its natural saturation level in a population. The revised peak calculation was influenced by evidence of a longer average period between HIV infection and death (from 9 to 11 years).

But the sharp decline in the total number of people living with HIV reflected in the 2007 UNAIDS/WHO report is mainly attributable to better estimation methods, indicating that the older numbers were too high. Using the more accurate estimation methods, the true figure for 2006 probably would have been around 32.7 million.

Previous global estimates from developing countries were largely based on HIV infection rates among women receiving prenatal care in urban clinics -- a group more likely to receive healthcare, including HIV tests, in resource-limited settings. This rate was then extrapolated to a country’s population as a whole to derive an estimate of the total number of infections.

Improved methods of tallying infections suggest that the old figures were an overestimate. More representative door-to-door household surveys in both urban and rural areas in Africa and other developing areas indicate that the rate of HIV infection among the population as a whole is lower than that among pregnant women (who, by definition, have had unprotected intercourse).

A large proportion of the decrease in the latest revised figures -- about 70% -- resulted from reducing the estimated number of infections in 5 countries in sub-Saharan Africa (Angola, Kenya, Mozambique, Nigeria, and Zimbabwe) and in India. The decline in India was particularly dramatic, from 5.7 million to 2.5 million infected people.

The reduction in the global HIV/AIDS estimate prompted some critics, including former UNAIDS epidemiologist James Chin, to accuse UNAIDS and WHO of intentionally inflating the earlier numbers to secure more funding for AIDS programs. Paul De Lay of UNAIDS called this claim “absurd,” stating “cooking this data would be almost impossible," since it is collected from multiple public health agencies in many countries.

While the decrease of 6 million cases is certainly welcome news, advocates emphasized that the AIDS pandemic is still a pressing global issue, affecting well over 30 million people worldwide, and that resources are still urgently needed to expand prevention efforts and provide treatment for all who need it.

“The fact is, the evolution of HIV prevention, treatment, and care over the past quarter century is one of the great successes of medical science,” the International AIDS Society said in a statement. “No one working around the world on HIV/AIDS wants anything other than to see the global statistics on HIV/AIDS drop to zero. Unfortunately we are a long way from achieving that dream. The gap between what is urgently needed and where we are today is nothing short of a crime against humanity.”

Regional Estimates

According to the latest UNAIDS/WHO report, the numbers of people living with

HIV in the various global regions are as follows:

  • Sub-Saharan Africa: 22.5 million;
  • North Africa/Middle East: 380,000;
  • South/Southeast Asia (including India): 4 million;
  • East Asia (including China): 800,000;
  • Oceania (including Australia/New Zealand): 75,000;
  • East Europe/Central Asia (including Russia): 1.6 million
  • West/Central Europe: 760,000;
  • North America (U.S. and Canada): 1.3 million;
  • Latin America (including Mexico): 1.6 million;
  • Caribbean: 230,000.

The full 2007 UNAIDS/WHO report on the global HIV/AIDS epidemic is available online.

Below is the text of a UNAIDS/WHO press release announcing the new data:

Global HIV prevalence has levelled off; AIDS is among the leading causes of death globally and remains the primary cause of death in Africa

Improvements in surveillance increase understanding of the epidemic, resulting in substantial revisions to estimates

Geneva, 20 November 2007 -- New data show global HIV prevalence -- the percentage of people living with HIV -- has levelled off and that the number of new infections has fallen, in part as a result of the impact of HIV programmes. However, in 2007 33.2 million [30.6 – 36.1 million] people were estimated to be living with HIV, 2.5 million [1.8 – 4.1 million] people became newly infected and 2.1 million [1.9 – 2.4 million] people died of AIDS.

There were an estimated 1.7 million [1.4 – 2.4 million] new HIV infections in sub-Saharan Africa in 2007 -- a significant reduction since 2001. However, the region remains most severely affected. An estimated 22.5 million [20.9 – 24.3 million] people living with HIV, or 68% of the global total, are in sub-Saharan Africa. Eight countries in this region now account for almost one-third of all new HIV infections and AIDS deaths globally.

Since 2001, when the United Nations Declaration of Commitment on HIV/AIDS was signed, the number of people living with HIV in Eastern Europe and Central Asia has increased by more than 150% from 630 000 [490 000 – 1.1 million] to 1.6 million [1.2 – 2.1 million] in 2007. In Asia, the estimated number of people living with HIV in Viet Nam has more than doubled between 2000 and 2005 and Indonesia has the fastest growing epidemic.

These findings were released today by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and the World Health Organization (WHO) in the report 2007 AIDS Epidemic Update.

Continuing improvements to latest estimates

The new report reflects improved and expanded epidemiological data and analyses that present a better understanding of the global epidemic. These new data and advances in methodology have resulted in substantial revisions from previous estimates.

While the global prevalence of HIV infection -- the percentage of people infected with HIV -- has levelled off, the total number of people living with HIV is increasing because of ongoing acquisition of HIV infection, combined with longer survival times, in a continuously growing general population.

Global HIV incidence -- the number of new HIV infections per year -- is now estimated to have peaked in the late 1990s at over 3 million [2.4 – 5.1 million] new infections per year, and is estimated in 2007 to be 2.5 million [1.8 – 4.1 million] new infections, an average of more than 6800 new infections each day. This reflects natural trends in the epidemic, as well as the result of HIV prevention efforts.

The number of people dying from AIDS-related illnesses has declined in the last two years, due in part to the life prolonging effects of antiretroviral therapy. AIDS is among the leading causes of death globally and remains the primary cause of death in Africa.

“These improved data present us with a clearer picture of the AIDS epidemic, one that reveals both challenges and opportunities,” said UNAIDS Executive Director Dr Peter Piot. “Unquestionably, we are beginning to see a return on investment—new HIV infections and mortality are declining and the prevalence of HIV levelling. But with more than 6 800 new infections and over 5700 deaths each day due to AIDS we must expand our efforts in order to significantly reduce the impact of AIDS worldwide.”

Revision of estimates

UNAIDS, WHO and the Reference Group on Estimates, Modelling and Projections have recently undertaken the most comprehensive review of their methodologies and monitoring systems since 2001. The epidemic estimates presented in this year’s report reflect improvements in country data collection and analysis, as well as a better understanding of the natural history and distribution of HIV infection. This information is vital in helping countries understand their epidemics and respond to them more effectively.

UNAIDS and WHO are now working with better information from many more countries. In the past few years a number of countries, most notably in sub-Saharan Africa and Asia, have expanded and improved their HIV surveillance systems, conducting new, more accurate studies that provide more precise information about HIV prevalence than earlier studies. In addition, 30 countries mostly in Africa have conducted national representative population-based household surveys. These have also informed adjustments for other countries with similar epidemics that have not conducted these surveys. New assumptions have also been made as a result of a better understanding of the natural history of untreated HIV infection.

The current estimate of 33.2 million [30.6 – 36.1 million] people living with HIV replaces the 2006 estimate of 39.5 million [34.1 – 47.1 million]. Applying the improved methodology retrospectively to the 2006 data, the 2007 report revises that figure, now estimating that in 2006 there were 32.7 million [30.2 – 35.3 million] people living with HIV. The single biggest reason for the reduction in global HIV prevalence figures in the past year was the recent revision of estimates in India after an intensive reassessment of the epidemic in that country. The revised estimates for India, combined with important revisions of estimates in five sub-Saharan African countries (Angola, Kenya, Mozambique, Nigeria, and Zimbabwe) account for 70% of the reduction in HIV prevalence as compared to 2006 estimates.

"Reliable public health data are the essential foundation for an effective response to HIV/AIDS", said WHO's HIV/AIDS Director Dr Kevin De Cock. "While these new estimates are of better quality than those of the past, we need to continue investing more in all countries and all aspects of strategic information relating to health."

"The data for measuring the HIV epidemic used by UNAIDS/WHO has considerably expanded and improved in recent years,” said Ron Brookmeyer, Professor of Biostatistics and Chair of the Master of Public Health Program, The Johns Hopkins Bloomberg School of Public Health. “Nevertheless, there is a need to further improve the representativeness of the underlying data. There is a need to expand disease surveillance systems to better track the sub-epidemics in risk populations within each county."

"More accurate estimates and trends will ultimately lead to improvements in the design and evaluation of prevention programmes," added Professor Brookmeyer, who was also the Chair of the Independent Review Panel at the recent International Consultation on epidemiological estimates convened by UNAIDS and WHO.

UNAIDS and WHO will continue to update their methodology as new data becomes available from research studies and surveillance data from countries.

Progress seen but more needs to be done

HIV prevalence among young pregnant women (15 – 24) attending antenatal clinics has declined since 2000/2001 in 11 of the15 most-affected countries. Preliminary data also show favourable changes in risk behaviour among young people in a number of countries, (Botswana, Cameroon, Chad, Haiti, Kenya, Malawi, Togo, Zambia, and Zimbabwe). These trends suggest that prevention efforts are having an impact in several of the most affected countries.

In sub-Saharan Africa, continued treatment scale-up and HIV prevention efforts are also bringing results in some countries, but mortality from AIDS remains high in Africa due to the extensive unmet treatment need. Cote d'Ivoire, Kenya and Zimbabwe, among others, have all seen downward trends in their national prevalence. Beyond sub-Saharan Africa, declines in new HIV infections have also occurred in South and South-East Asia, notably in Cambodia, Myanmar and Thailand.

There is a need to adapt and revive HIV prevention efforts as some countries are seeing a reversal of declining trends. Burundi’s declining trend from the late 1990’s did not continue beyond 2005 and HIV prevalence started to increase again at most surveillance sites. Despite achievements in reversing the epidemic in Thailand, HIV prevalence is rising among men who have sex with men and has remained high among injecting drug users over the past 15 years, ranging between 30% to 50%.

UNAIDS and WHO officials point out that the new estimates do not change the need for immediate action and increased funding to scale up towards universal access to HIV prevention, treatment, care and support services.

11/30/07

Sources

UNAIDS and World Health Organization. AIDS Epidemic Update 07. December 2007.

UNAIDS and World Health Organization. Global HIV prevalence has levelled off; AIDS is among the leading causes of death globally and remains the primary cause of death in Africa. Press release. November 20, 2007.

International AIDS Society. New HIV Estimates Confirm that HIV/AIDS Is Still a Leading Cause of Death Worldwide. Press release. November 21, 2007.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

FDA-Approved
Treatments
Protease Inhibitors
Agenerase
Agenerase (amprenavir)
Aptivus
Aptivus (tipranavir)
Crixivan
Crixivan (indinavir)
Invirase
Invirase (saquinavir hard gel)
Kaletra
Kaletra (lopinavir/ritonavir)
Lexiva
Lexiva (fosamprenavir)
Norvir
Norvir (ritonavir)
Prezista
Prezista (darunavir)
Reyataz
Reyataz (atazanavir)
ViraceptViracept (nelfinavir)
Nucleoside / Nucleotide Reverse Transcriptase Inhibitors
CombivirCombivir (zidovudine/lamivudine)
EpivirEpivir (lamivudine; 3TC)
EmtrivaEmtriva (emtricitabine; FTC)
EpzicomEpzicom (abacavir + lamivudine)
RetrovirRetrovir (zidovudine; AZT)
TrizivirTrizivir (abacavir + zidovudine +lamivudine)
TruvadaTruvada  (tenofovir / emtricitabine)
VidexVidex (didanosine; ddI)
VireadViread (tenofovir)
ZeritZerit (stavudine; d4T)
ZiagenZiagen (abacavir)
non Nucleoside Reverse
Transcriptase Inhibitors
RescriptorRescriptor (delavirdine)
SustivaSustiva (efavirenz)
ViramuneViramune (nevirapine)
Entry Inhibitors
(including Fusion Inhibitors)
Fuzeon (enfuvirtide, T-20)
Selzentry ( maraviroc)
Fixed-dose Combinations
AtriplaAtripla (efavirenz + emtricitabine + tenofovir)
CombivirCombivir (zidovudine + lamivudine)
TrizivirTrizivir (abacavir + zidovudine + lamivudine)
TruvadaTruvada (tenofovir + emtricitabine)